On February 8, according to the official website of NMPA, the drug marketing application for "Secukinumab Injection" (BAT2306) submitted by BioAtla was accepted. This is the first secukinumab biosimilar to be submitted for marketing.
According to data, the original research secukinumab is a fully human IgG1 monoclonal antibody developed by Novartis that can selectively bind to the cytokine interleukin 17A (IL-17A) and inhibit its interaction with the IL-17 receptor.
In December 2014, Secukinumab (trade name: Cosentyx) was first approved for marketing for the treatment of psoriatic arthritis.
In March 2019, Secukinumab was approved for marketing in China under the trade name Cosentyx.
So far, Novartis' Secukinumab has been approved for marketing in many countries and regions around the world, including Japan, the European Union, the United States, and China, involving multiple indications such as psoriatic arthritis, psoriasis vulgaris, plaque psoriasis, ankylosing spondylitis, and pustular psoriasis, and all indications have been included in medical insurance this year. Its annual sales have also been rising. According to Novartis' 2024 annual report, Cosentyx's revenue in 2024 will reach US$6.141 billion.
According to data, there are a total of 6 secukinumab biosimilars under clinical development worldwide, of which 4 have entered the late development stage, including BAT2306, CMAB015 (Mabiotech), SYS6012 (Shijiazhuang Pharmaceutical Group) and CT-P55 (Celltrion).

https://news.yaozh.com/archive/44957.html